Literature DB >> 8107240

Viral multiplicity of attachment and its implications for human immunodeficiency virus therapies.

J L Spouge1.   

Abstract

The multiplicity of attachment (MOA) of a virion in any particular time interval is the average number of cellular attachment opportunities that must be blocked to keep the virion in suspension. MOA is usually proportional to incubation time and cell concentration. Low MOA (like low multiplicity of infection) is required for reproducible assay of adsorptive blockers, and high MOA by itself can produce spurious synergies between adsorptive blockers, e.g., soluble CD4 (sCD4) and some antibodies. Poliovirus and human immunodeficiency virus (HIV) data show that viral neutralization conforms quantitatively to MOA and kinetic theory over large ranges of incubation times and target cell concentrations. Extrapolating sCD4 data beyond conditions achievable in vitro to those in vivo predicts that sCD4 concentrations above the strain-specific sCD4-gp120 dissociation constant are required to block lymphoid HIV significantly, in at least semiquantitative agreement with clinical results. The extrapolation is applicable to humoral neutralization data as well. MOA analysis also indicates that although completely stopping the attachment of individual virions to cells may still be an effective therapeutic strategy against established HIV infection, merely retarding attachment probably is not. The concept of MOA holds great promise for improving the therapeutic relevance of in vitro data and can be applied to any infectious agent, to many processes that impair or enhance infection steps, and to many assay end points, not just infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8107240      PMCID: PMC236639     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Symposium on the biology of cells modified by viruses or antigens. III. Physiological conditions for studies of viral biosynthesis in mammalian cells.

Authors:  A F GRAHAM
Journal:  Bacteriol Rev       Date:  1959-12

2.  Soluble CD4: the first step.

Authors:  E C Tramont; R R Redfield
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

3.  Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4.

Authors:  J P Moore
Journal:  AIDS       Date:  1990-04       Impact factor: 4.177

Review 4.  [Primates as a model for the study of lentiviruses and AIDS].

Authors:  D Dormont
Journal:  Pathol Biol (Paris)       Date:  1990-03

5.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

Authors:  E S Daar; X L Li; T Moudgil; D D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  Quantifying the infectivity of human immunodeficiency virus.

Authors:  S P Layne; J L Spouge; M Dembo
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

7.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4.

Authors:  J P Moore; J A McKeating; R A Weiss; Q J Sattentau
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

8.  Neutralization of poliovirus by cell receptors expressed in insect cells.

Authors:  G Kaplan; M S Freistadt; V R Racaniello
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

9.  HIV requires multiple gp120 molecules for CD4-mediated infection.

Authors:  S P Layne; M J Merges; M Dembo; J L Spouge; P L Nara
Journal:  Nature       Date:  1990-07-19       Impact factor: 49.962

10.  Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial.

Authors:  R T Schooley; T C Merigan; P Gaut; M S Hirsch; M Holodniy; T Flynn; S Liu; R E Byington; S Henochowicz; E Gubish
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

View more
  10 in total

1.  Neutralization profiles of sera from human immunodeficiency virus (HIV)-infected individuals: relationship to HIV viral load and CD4 cell count.

Authors:  M Nokta; P Turk; K Loesch; R B Pollard
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

2.  A practical method for simultaneously determining the effective burst sizes and cycle times of viruses.

Authors:  J L Spouge; S P Layne
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

3.  Murine leukemia virus envelope protein in transgenic-mouse serum blocks infection in vitro.

Authors:  A Nihrane; K Fujita; R Willey; M S Lyu; J Silver
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

Review 4.  Virus receptors: implications for pathogenesis and the design of antiviral agents.

Authors:  L C Norkin
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

5.  Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.

Authors:  John R Mascola; Mark K Louder; Christine Winter; Ranjani Prabhakara; Stephen C De Rosa; Daniel C Douek; Brenna J Hill; Dana Gabuzda; Mario Roederer
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.

Authors:  P J Klasse; J P Moore
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

7.  Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages.

Authors:  S C Wu; J L Spouge; S R Conley; W P Tsai; M J Merges; P L Nara
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

8.  Phage therapy dosing: The problem(s) with multiplicity of infection (MOI).

Authors:  Stephen T Abedon
Journal:  Bacteriophage       Date:  2016-08-11

9.  Estimating the basic reproduction number of a pathogen in a single host when only a single founder successfully infects.

Authors:  Vruj Patel; John L Spouge
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240

Review 10.  Phage therapy: eco-physiological pharmacology.

Authors:  Stephen T Abedon
Journal:  Scientifica (Cairo)       Date:  2014-05-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.